AVR 0.00% $18.00 anteris technologies ltd

Vaxxas secures funding interest to see if professor Fraser utilizes nanopatch, page-115

  1. 528 Posts.
    lightbulb Created with Sketch. 36
    The Vaxaas nano patch may well be used in the next trials. That would be an interesting validation of both technologies.

    I wonder what the commercials around that might look like? Would we be the first significant use?

    Trials will at some point need to be on the whole system, not just the vaccine. I'm intrigued if that will start from phase 2b.
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.